In addition, treatment of NSCLC cells with EGFR tyrosine kinase inhibitors (EGFR-TKIs) can downregulate the activation of the IL-6/JAK/STAT3 pathway, which subsequently leads to the reduced expression of PD-L1 [22]. The gene discussed is IL6; the disease is non-small cell lung carcinoma.